Article

Able Labs Files for Chapter 11

Able Labs Files for Chapter 11

Able Laboratories (Cranbury, NJ) filed for voluntary Chapter 11 reorganization in the New Jersey division of the United States Bankruptcy Court on Monday. This announcement comes on the heels of last week’s resignation of company President and interim CEO Robert G. Mauro.

In Late May, the company was forced to halt all production and recall all available product after an internal investigation turned up problematic testing procedures. Citations by the US Food and Drug Administration include Citations include: failure to ensure that all drug product distributed had the safety, identity, quality, and purity that they are represented to possess; failure to reject drug products that failed to meet established standards, specifications, and quality control criteria.

The Chapter 11 filing will allow Able to continue as a company while working with FDA to improve the aforementioned failings, and cover all expenses to vendors and suppliers.

–George Koroneos

Newsletter

Get the essential updates shaping the future of pharma manufacturing and compliance—subscribe today to Pharmaceutical Technology and never miss a breakthrough.

Related Videos
A global supply chain map, visualizing the complex network of transportation routes and distribution centers | Image Credit: © venusvi - stock.adobe.com
Shortcut from point A to point B | Image Credit: © Olivier Le Moal - stock.adobe.com
Behind the Headlines, Episode 21: Waters-BD Merger, Merck’s $10B Bet, and Biotech’s Investment Frontiers
Wooden blocks spelling TARIFFS are placed on a map of North America, specifically over the United States and Mexico | Image Credit: © Rokas - stock.adobe.com
Jason Waite, International Trade Expert, Alston & Bird
Simona Guidi, Associate Director, ProPharma
Tore Bergsteiner
Behind the Headlines, Episode 20: CAR-T Milestones, Abbvie and Eli Lilly M&A Moves, and More